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Background: COVID-19–related critical illness is associated with an increased risk of venous
thromboembolism (VTE).
Objective: These evidence-based guidelines of the American Society of Hematology (ASH) are
intended to support patients, clinicians, and other health care professionals in making decisions
about the use of anticoagulation for thromboprophylaxis in patients with COVID-19–related critical illness who do not have conﬁrmed or suspected VTE.
Methods: ASH formed a multidisciplinary guideline panel that included 3 patient representatives
and applied strategies to minimize potential bias from conﬂicts of interest. The McMaster University
Grading of Recommendations Assessment, Development and Evaluation (GRADE) Centre supported
the guideline development process by performing systematic evidence reviews (up to 5 March 2021).
The panel prioritized clinical questions and outcomes according to their importance for clinicians and
patients. The panel used the GRADE approach to assess evidence and make recommendations,
which were subject to public comment. This is an update on guidelines published in February 2021.
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Results: The panel agreed on 1 additional recommendation. The panel issued a conditional
recommendation in favor of prophylactic-intensity over intermediate-intensity anticoagulation in
patients with COVID-19–related critical illness who do not have conﬁrmed or suspected VTE.
Conclusions: This recommendation was based on low certainty in the evidence, which underscores
the need for additional high-quality, randomized, controlled trials comparing different intensities of anticoagulation in critically ill patients. Other key research priorities include better evidence regarding predictors of thrombosis and bleeding risk in critically ill patients with COVID-19 and the impact of
nonanticoagulant therapies (eg, antiviral agents, corticosteroids) on thrombotic risk.

Recommendation 1a
The American Society of Hematology (ASH) guideline panel suggests using prophylactic-intensity over intermediate-intensity anticoagulation in patients with COVID-19–related critical illness who do
not have suspected or conﬁrmed venous thromboembolism (VTE)
(conditional recommendation based on low certainty in the evidence
).
about effects ⨁⨁

function, history of heparin-induced thrombocytopenia, concerns
about gastrointestinal tract absorption).
 This recommendation does not apply to patients who require
anticoagulation to prevent thrombosis of extracorporeal circuits
such as those on extracorporeal membrane oxygenation or continuous renal replacement therapy.

Remarks:

Background

 The ASH guideline panel plans to continue to update this recommendation when the full results of other trials become available.
Clinicians should weigh the beneﬁts and harms based on the
most up-to-date evidence in caring for their patients.
 A now-expired recommendation published on 27 October
2020 compared therapeutic-intensity or intermediate-intensity
with prophylactic-intensity anticoagulation in patients with
COVID-19–related critical illness. With the emergence of new
evidence, this recommendation has now been split into 2 recommendations: a recommendation comparing intermediateintensity with prophylactic-intensity anticoagulation (Recommendation 1a) and a separate recommendation comparing
therapeutic-intensity with prophylactic-intensity anticoagulation
(Recommendation 1b), whereby the latter remains unchanged
for now, but, as with other recommendations in this guideline, is
subject to review and revision as new evidence becomes
available that meets prespeciﬁed criteria for updating.
 Patients with COVID-19–related critical illness are deﬁned as
those suffering from an immediately life-threatening condition
who would typically be admitted to an intensive care unit (ICU).
Examples include patients requiring hemodynamic support, ventilatory support, and renal replacement therapy.
 An individualized assessment of the patient’s risk of thrombosis
and bleeding is important when deciding on anticoagulation
intensity. Risk assessment models to estimate thrombotic
and bleeding risk in hospitalized patients are available, but
they have not been prospectively validated in patients with
COVID-19.
 At present, there is no direct high-certainty evidence comparing
different types of anticoagulants. The selection of a speciﬁc
agent (eg, low molecular weight heparin [LMWH], unfractionated heparin [UFH]) may be based on availability, resources
required, familiarity, and the aim of minimizing the use of personal
protective equipment or exposure of staff to COVID19–infected patients as well as patient-speciﬁc factors (eg, renal

There is a high incidence of thrombotic complications in critically
ill patients with COVID-19.1 VTE is the most common thrombotic
complication and has been reported in up to 23% of critically ill
patients with COVID-19.2 Consequently, there has been intense
clinical and research interest in establishing whether intensiﬁed
thromboprophylaxis regimens are needed in this population.3
However, critically ill patients may be at increased risk for bleeding complications, which may also occur in patients with COVID19–related critical illness.4-8 The optimal strategy for thromboprophylaxis that balances these thrombosis and bleeding risks
remains uncertain.
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These guidelines are based on updated and original systematic
reviews of evidence conducted under the direction of the McMaster University Grading of Recommendations Assessment, Development and Evaluation (GRADE) Centre with international
collaborators. This is an update of the previous ASH guideline
published in February 2021,9 and it focuses on intermediateintensity vs prophylactic-intensity anticoagulation. The panel followed best practices for guideline development recommended by
the Institute of Medicine and the Guidelines International Network.10-12 The panel used the GRADE approach13-19 to assess
the certainty of the evidence and formulate recommendations. The
recommendation is listed in Table 1.

Values and preferences
 The guideline panel identiﬁed all-cause mortality, pulmonary
embolism (PE), deep vein thrombosis (DVT), and major bleeding
as critical outcomes and placed a high value on avoiding these
outcomes with the interventions assessed.
 Panel members noted that there was possible uncertainty and
variability in the relative value that patients place on avoiding
major bleeding events compared with reducing thrombotic
events.
26 OCTOBER 2021 • VOLUME 5, NUMBER 20
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Summary of recommendations

Explanations and other considerations
Please refer to the original ASH guideline on thromboprophylaxis in
patients with COVID-19.9

Interpretation of strong and conditional
recommendations
Please refer to the original ASH guideline on thromboprophylaxis in
patients with COVID-19.9

Introduction
Aims of these guidelines and specific objectives

Description of the health problem
The COVID-19 pandemic has had a signiﬁcant public health impact.
As of 2 May 2021, more than 152 million cases and 3.2 million
deaths had been attributed to COVID-19–related illness globally.20
It is estimated that 5% to 20% of infected patients require hospital
admission, of whom 5% to 15% may develop critical illness requiring intensive care support.21-23
Patients with critical illness resulting from COVID-19 may develop a
severe inﬂammatory response and endothelial dysfunction, which
may result in platelet activation, activation of the coagulation cascade, and a hypercoagulable state.24 Several laboratory predictors
of thrombosis in hospitalized patients with COVID-19 have been
reported, including elevated D-dimer, C-reactive protein, and erythrocyte sedimentation rate.5,25 VTE has emerged as an important complication in critically ill patients with COVID-19, occurring in up to
23% of such patients.2 This was observed in the very early days of
the pandemic, but it remains an important issue, even with the introduction of improved treatments in subsequent waves of the pandemic.26,27 In addition, arterial thrombotic complications including
stroke have been noted.28,29 Microvascular thrombosis, which may
involve the pulmonary vasculature and other organs, has been
reported in autopsy studies, although its impact on the development

The optimal thromboprophylaxis strategy that balances thrombotic
and bleeding risk in critically ill patients with COVID-19 remains
uncertain.32-35 This uncertainty has led to variability in clinical practice regarding empiric thromboprophylaxis regimens, and several
randomized trials are in progress.36,37 Although COVID19–associated coagulopathy seems to be marked primarily by
thrombotic complications, patients may develop major bleeding
complications when receiving anticoagulation therapy, which can
have an impact on the safety of intensiﬁed thromboprophylaxis regimens.5,8,38 In this living guideline update, the role of intermediatevs prophylactic-intensity anticoagulation in critically ill patients with
COVID-19 is addressed.

Description of the target populations
The target population, patients with COVID-19–related critical illness, is described in Table 2.

Methods
This updated guideline recommendation on the use of intermediateintensity anticoagulation in critically ill patients was developed in the
living phase of the ASH 2021 living guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19. The

Table 1. Recommendations
Recommendation

Remarks

Recommendation 1a. The ASH guideline panel suggests using
prophylactic-intensity over intermediate-intensity anticoagulation in
patients with COVID-19–related critical illness who do not have
suspected or conﬁrmed VTE (conditional recommendation based on
low certainty in the evidence about effects ⨁⨁
).

 The ASH guideline panel plans to continue to update this recommendation when the full results of
other trials become available. Clinicians should weigh the potential beneﬁts and harms based on the
most up-to-date evidence in caring for their patients.
 A now-expired recommendation published on 27 October 2020 compared therapeutic-intensity or
intermediate-intensity with prophylactic-intensity anticoagulation in patients with COVID-19–related
critical illness. With the emergence of new evidence, this recommendation has now been split into 2
recommendations: a recommendation comparing intermediate-intensity vs prophylactic-intensity
anticoagulation (Recommendation 1a) and a separate recommendation comparing therapeuticintensity vs prophylactic-intensity anticoagulation (Recommendation 1b), whereby the latter remains
unchanged for now, but, as with other recommendations in this guideline, is subject to review and
revision as new evidence becomes available that meets prespeciﬁed criteria for updating.
 Patients with COVID-19–related critical illness are deﬁned as those suffering from an immediately lifethreatening condition who would typically be admitted to an ICU. Examples include patients requiring
hemodynamic support, ventilator support, and renal replacement therapy.
 An individualized assessment of the patient’s risk of thrombosis and bleeding is important when
deciding on anticoagulation intensity. Risk assessment models to estimate thrombotic and bleeding
risk in hospitalized patients are available, but they have not been prospectively validated in patients
with COVID-19.
 At present, there is no direct high-certainty evidence comparing different types of anticoagulants. The
selection of a speciﬁc agent (eg, LMWH, UFH) may be based on availability, resources required,
familiarity, and the aim of minimizing the use of personal protective equipment or staff exposure to
COVID-19–infected patients as well as patient-speciﬁc factors (eg, renal function, history of heparininduced thrombocytopenia, concerns about gastrointestinal tract absorption).
 This recommendation does not apply to patients who require anticoagulation to prevent thrombosis of
extracorporeal circuits such as those on extracorporeal membrane oxygenation or continuous renal
replacement therapy.
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Please refer to the original ASH guideline on thromboprophylaxis in
patients with COVID-19.9

of respiratory and multiorgan failure remains unclear.30,31 Patients
who are critically ill may also be at increased bleeding risk, which
may be a result of platelet dysfunction, thrombocytopenia, organ
dysfunction, or consumptive coagulopathy.4,5

Table 2. Deﬁnition of target population
Target population
Critically ill

Definition
Patients with COVID-19 who develop respiratory or
cardiovascular failure normally requiring advanced
clinical support in the ICU or critical care unit (CCU)
but could include admission to another department if
the ICU/CCU was over capacity. ICU/CCU capacity
and admission criteria could vary according to the
speciﬁc setting.

We followed the same methods as published in the initial guideline,9
with the following important updates and differences for the recommendation reported here:
 Organization, panel composition, planning, and coordination:
With one exception, we retained the same panel members
because no conﬂicts of interest emerged that would require
exclusion of panel members.
 Guideline funding and management of conﬂicts of interest: Supplement 4 provides updated “Participant Information Forms” for
all panel members, detailing ﬁnancial and nonﬁnancial interests,
as well as the ASH conﬂict-of-interest policies agreed to by
each individual. Supplement 5 provides the updated complete
Participant Information Forms for researchers on the Systematic
Review Team who contributed to these guidelines.
 Formulating speciﬁc clinical questions and determining outcomes of interest: This updated manuscript focuses on 1 question: In patients with COVID-19–related critical illness who do
not have conﬁrmed or suspected VTE, should we use direct oral
anticoagulants, LMWH, UFH, fondaparinux, argatroban, or bivalirudin at intermediate intensity or prophylactic intensity? There
were no changes in the deﬁnitions for population (Table 2), anticoagulation intensity, or outcomes.9
 Evidence review and development of recommendations: A new
evidence-to-decision (EtD) framework was created for Recommendation 1a (see Recommendations) that uses any applicable
evidence and information from the EtD framework for the initial
Recommendation 1, and it will be updated with new evidence
and considerations speciﬁcally for Recommendation 1a. The
systematic review to identify comparative antithrombotic studies
for the entire guideline was updated until 5 March 2021, the literature search strategy (Supplement 6) was modiﬁed only to
add search terms for antiplatelet agents for another guideline
question, and the protocol (Supplement 9) was modiﬁed to
focus on inclusion of only randomized controlled trials for the
guideline after the initial phase. Baseline risk estimates for outcomes in patients with COVID-19–related critical illness were
not updated. The decision to create this updated guideline recommendation was based on publication of the INSPIRATION
trial,39 which was not yet included in the systematic literature
searches but was identiﬁed by expert panel members, critically
assessed by the evidence synthesis team, and determined to
increase the certainty of the evidence for several critical
outcomes.
 Document review: The draft recommendation was reviewed by all
members of the panel, revised, and then made available online
from 21 to 28 April 2021 for external review by stakeholders,
including allied organizations, other medical professionals,
3954
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Recommendations
Recommendation 1a
Should direct oral anticoagulants, LMWH, UFH, fondaparinux, argatroban, or bivalirudin at intermediate-intensity vs prophylacticintensity be used for patients with COVID-19–related critical illness
who do not have suspected or conﬁrmed VTE?

Recommendation 1a
The ASH guideline panel suggests using prophylactic-intensity
over intermediate-intensity anticoagulation in patients with
COVID-19–related critical illness who do not have suspected
or conﬁrmed VTE (conditional recommendation based on low
).
certainty in the evidence about effects ⨁⨁
Remarks:
 The ASH guideline panel plans to continue to update
this recommendation when the full results of other trials
become available. Clinicians should weigh the beneﬁts
and harms based on the most up-to-date evidence in
caring for their patients.
 A now-expired recommendation published on 27 October
2020 compared therapeutic-intensity or intermediateintensity with prophylactic-intensity anticoagulation in
patients with COVID-19–related critical illness. With the
emergence of new evidence, this recommendation has now
been split into 2 recommendations: a recommendation
comparing intermediate-intensity with prophylactic-intensity
anticoagulation (Recommendation 1a) and a separate recommendation comparing therapeutic-intensity with
prophylactic-intensity anticoagulation (Recommendation
1b), whereby the latter remains unchanged for now but, as
with other recommendations in this guideline, is subject to
review and revision as new evidence becomes available
that meets prespeciﬁed criteria for updating.
 Patients with COVID-19–related critical illness are
deﬁned as those suffering from an immediately lifethreatening condition who would typically be admitted to
an intensive care unit. Examples include patients requiring hemodynamic support, ventilatory support, and renal
replacement therapy.
 An individualized assessment of the patient’s risk of
thrombosis and bleeding is important when deciding on
anticoagulation intensity. Risk assessment models to
estimate thrombotic and bleeding risk in hospitalized
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ASH guideline panel generated Recommendation 1a on 30 March
2021 before asking for public comments.

patients, and the public. Two individuals or organizations submitted responses that did not require changes to the document. On
1 June 2021, the ASH Guideline Oversight Subcommittee and
the ASH Committee on Quality veriﬁed that the deﬁned guideline
development process was followed, and on 3 June 2021, the ofﬁcers of the ASH Executive Committee approved submission of the
updated guideline manuscript for publication under the imprimatur
of ASH. The updated guideline manuscript was then subjected to
peer review by Blood Advances.
 How to use these guidelines: We refer readers to the description in the initial guideline publication from February 2021,9
as well as the user guide for the ASH clinical practice
guidelines.40

Summary of the evidence. We rated the certainty in the evidence as moderate for the outcomes of ventilator-free days and
length of ICU stay owing to serious imprecision, and as low for all
other outcomes owing to very serious imprecision (see evidence
proﬁle and EtD online at https://guidelines.ash.gradepro.org/proﬁle/
iqf3QTwLZt0). We found no systematic reviews that addressed this
question. There was 1 randomized controlled trial that provided evidence related to this question.39 Supplement 10 presents the characteristics of the included study.
One randomized controlled trial reported the effect of intermediateintensity anticoagulation on all-cause mortality, PE, DVT, VTE, major
bleeding, renal replacement therapy, ischemic stroke, intracranial
hemorrhage, ventilator-free days, length of ICU stay, and myocardial
infarction.39 No studies reported the effect of intermediate-intensity
anticoagulation on multiorgan failure or limb amputation.
Benefits. Intermediate-intensity anticoagulation may reduce the risk
of PE but the evidence is uncertain (odds ratio [OR], 0.41; 95%
conﬁdence interval [CI], 0.08-2.13); this corresponds to 55 fewer
(from 89 fewer to 90 more) PEs per 1000 patients; low certainty.39
Taking PE and DVT together, intermediate-intensity anticoagulation
may reduce the risk of VTE, but the evidence is uncertain (OR,
0.93; 95% CI, 0.37-2.32); this corresponds to 8 fewer (from 78
fewer to 127 more) VTE events per 1000 patients; low certainty.
Intermediate-intensity anticoagulation may reduce the length of ICU
stay, but the evidence is uncertain (mean difference, 1 day fewer;
95% CI, 4 days fewer to 3 days more); moderate certainty.
Intermediate-intensity anticoagulation had no effect on ventilator-free
days, but the evidence is uncertain (mean difference, 0 days; 95%
CI, 0-0 days); moderate certainty.
Harms and burden. Intermediate-intensity anticoagulation may
increase the risk of all-cause mortality, but the evidence is uncertain
(OR, 1.09; 95% CI, 0.78-1.53); this corresponds to 16 more (from
42 fewer to 85 more) deaths per 1000 patients; low certainty.39
Intermediate-intensity anticoagulation may increase the risk of DVT,
but the evidence is uncertain (OR, 1.46; 95% CI, 0.46-4.66); this
corresponds to 42 more (from 54 fewer to 250 more) DVTs per
1000 patients; low certainty. Intermediate-intensity anticoagulation
may increase the risk of major bleeding, but the evidence is
26 OCTOBER 2021 • VOLUME 5, NUMBER 20

uncertain (OR, 1.83; 95% CI, 0.53-5.93); this corresponds to 60
more (from 38 fewer to 268 more) major bleeding events per 1000
patients; low certainty. Intermediate-intensity anticoagulation may
increase the use of renal replacement therapy, but the evidence is
uncertain (OR, 1.49; 95% CI, 0.58-3.86); this corresponds to 125
more (from 48 fewer to 230 more) uses of renal replacement therapy per 1000 patients; low certainty. The effect of intermediateintensity anticoagulation on the outcomes of ischemic stroke, intracranial hemorrhage, and myocardial infarction was very uncertain
because only 1 ischemic stroke, 1 intracranial hemorrhage, and no
myocardial infarctions occurred in the trial.
Other EtD criteria and considerations. The guideline panel
noted that there was possible uncertainty and variability in the relative value patients place on reducing thrombotic events compared
with avoiding major bleeding events. The panel agreed that the use
of intermediate-intensity anticoagulation would be acceptable to
patients and health care providers. However, given the low certainty
in the evidence, there may be regional variation in the acceptability
of intermediate-intensity anticoagulation, particularly in regions where
baseline VTE risk may be lower (eg, Asian populations).41,42
The panel recognized that COVID-19 disproportionately affects certain racial and ethnic groups, including Black and Hispanic individuals. However, the use of intermediate-intensity anticoagulation was
judged to probably not have a differential impact on health equity
relative to the use of prophylactic-intensity anticoagulation. Although
intermediate-intensity anticoagulation would result in a higher cost
for drugs, the panel judged this difference to be negligible relative
to the total costs of providing critical care.
Conclusions. The panel judged that there was low certainty evidence in the desirable and undesirable effects of intermediateintensity anticoagulation in patients with COVID-19–related critical
illness. There was a suggestion of a reduction in PE with
intermediate-intensity anticoagulation, but the opposite was
observed for DVT, and the evidence for both outcomes was of
low certainty.
Meanwhile, there was less uncertainty in the potential undesirable
effects of intermediate-intensity anticoagulation with respect to
increased risk of major bleeding complications. The panel considered that there was higher-quality indirect evidence from critically ill
patients who did not have COVID-19 for a dose-dependent
increase in the risk of major bleeding with anticoagulation, although
the magnitude of this effect was of low certainty in the population
who did have COVID-19.8,43-46 Given that there was low certainty
for potential beneﬁt to offset the moderate risk of major bleeding
complications, the usual practice of prophylactic-intensity anticoagulation, as used in critically ill patients who did not have COVID-19,
was suggested.47
However, the panel noted that an individualized decision is important for each patient based on an assessment of thrombosis and
bleeding risk. Dose adjustment of prophylactic-intensity anticoagulation for extremes of body weight or renal impairment may also be
considered.48-52
This recommendation does not apply to thrombotic complications
related to extracorporeal circuits. Although high rates of circuitrelated thrombosis during extracorporeal membrane oxygenation
ASH GUIDELINES ON ANTICOAGULATION IN COVID-19 3955

Downloaded from http://ashpublications.org/bloodadvances/article-pdf/5/20/3951/1827531/advancesadv2021005493c.pdf by guest on 17 December 2021

patients are available, but they have not been
prospectively validated in patients with COVID-19.
 At present, there is no direct high-certainty evidence
comparing different types of anticoagulants. The selection of a speciﬁc agent (eg, LMWH or UFH) may be
based on availability, resources required, familiarity, and
the aim of minimizing the use of personal protective
equipment or staff exposure to COVID-19–infected
patients as well as patient-speciﬁc factors (eg, renal
function, history of heparin-induced thrombocytopenia,
concerns about gastrointestinal tract absorption).
 This recommendation does not apply to patients who
require anticoagulation to prevent thrombosis of
extracorporeal circuits such as those on extracorporeal
membrane oxygenation or continuous renal replacement
therapy.

and continuous renal replacement therapy have been reported in
patients with COVID-19, this outcome was not prioritized by the
guideline panel as part of its systematic review of the evidence.53

What are others saying and what is new in
these guidelines?

Major differences between the current ASH guidelines and these
other documents include use of high-quality systematic reviews and
EtD frameworks, which increase transparency, along with use of
marker states to estimate the relative importance to patients as key
outcomes of treatment. This ASH guideline is also unique in its
“living” format, which enables the inclusion of the recently published
INSPIRATION clinical trial39 to inform the current recommendation
(most other guidance documents were published before this trial’s
results were made available; they may be revised as new evidence
becomes available).
Four of the 5 other guidance documents (NIH, ISTH, ACC, and
CHEST) suggest that prophylactic-dose heparin (either UFH or
LMWH) be used for thromboprophylaxis in critically ill patients with
COVID-19 over higher-intensity anticoagulation. They acknowledge
that although there is an increased risk of VTE in hospitalized
patients with COVID-19, there is insufﬁcient randomized data at this
time to recommend increased-intensity anticoagulation. The ISTH
guidance document suggests that intermediate-dose LMWH could
be considered in high-risk patients, and that patients with obesity
could be considered for a 50% empiric dose increase for thromboprophylaxis. The ISTH document also suggests that multimodal prophylaxis with mechanical methods should be considered. This is
notable because current guidelines in critically ill patients who do
not have COVID-19 suggest using pharmacologic prophylaxis alone
over combined pharmacologic and mechanical prophylaxis.47,59
Meanwhile, the guidance document from the AC Forum suggests
that in critically ill patients with COVID-19, intermediate or increased
intensities of thromboprophylaxis could be used.55 The authors
acknowledge that this was based on expert opinion, and this was
published before the results of the INSPIRATION randomized trial
were made available.39
At the time of this writing, there has been only 1 small published
randomized trial in critically ill patients with COVID-19 that compares therapeutic-dose and prophylactic-dose anticoagulation.60
Although this trial demonstrated improvements in gas exchange
(PaO2:FiO2 ratio) with therapeutic anticoagulation, deﬁnitive conclusions cannot be drawn because only 20 patients were enrolled. A
second randomized trial, the ACTION trial, compared therapeuticintensity vs prophylactic-intensity anticoagulation in hospitalized
patients with COVID-19 and elevated D-dimer. Most of the patients
did not have critical illness. Therapeutic-intensity anticoagulation did
not improve clinical outcomes and was associated with increased
bleeding.61 A multiplatform study (ACTIV-4/REMAP-CAP/ATTACC)
3956
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Limitations of this guideline
The limitations of these guidelines are inherent in the low certainty
of the evidence we identiﬁed for the research questions. There were
2 outcomes that were identiﬁed as critical for decision making by
the guideline panel for which no direct evidence was available (multiple organ failure and limb amputation).
In addition, the use of treatments other than anticoagulants for management of COVID-19–related critical illness (eg, corticosteroids,
anticytokine therapies, ventilatory support) as well as the emergence
of different viral variants has changed over the course of the pandemic. These changes may impact the baseline risk of VTE. Evidence collected earlier in the pandemic and included in our
systematic reviews may not fully reﬂect the baseline risk of VTE or
the effect of different intensities of anticoagulation in the current
state of the pandemic.

Revision or adaptation of the guideline
Plans for updating these guidelines
The reported recommendation is the ﬁrst living update of recommendations from the initial guideline publication that will be maintained by ASH through surveillance for new evidence, ongoing
review by experts, and regular revisions. See the initial guideline
publication for methods of living systematic reviews and recommendations, including considerations for deciding when to reassess and
update recommendations.9

Updating or adapting recommendations locally
Adaptation of these guidelines will be necessary in many circumstances. These adaptations should be based on the associated EtD
frameworks.17

Priorities for research
On the basis of gaps in evidence identiﬁed during the guideline
development process, the panel identiﬁed the following urgent
research priorities in this patient population:
 Studies assessing baseline VTE risk in critically ill patients
receiving prophylactic-intensity anticoagulation therapy
 Randomized controlled trials comparing anticoagulation at differing intensities (prophylactic vs intermediate vs therapeutic)
 Studies examining the impact of nonanticoagulant interventions
(eg, anticomplement therapy, corticosteroids, antiviral therapies,
anticytokine therapies, antiplatelet therapies, monoclonal
antibody therapy, convalescent plasma) on thrombotic risk
 Development or validation of risk assessment models for thrombosis and bleeding in patients with COVID-19–related critical
illness
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There are multiple other guidance documents on the use of anticoagulation in patients with COVID-19. These include the 2020
CHEST COVID-19 Guidelines, the Anticoagulation (AC) Forum
interim clinical guidance, the International Society on Thrombosis
and Haemostasis (ISTH) Scientiﬁc and Standardization Committee
(SSC) COVID-19 clinical guidance, the National Institutes of Health
(NIH) COVID-19 treatment guidelines, and the American College of
Cardiology (ACC) clinical guidance.54-58

in critically ill patients with COVID-19 comparing therapeutic- with
prophylactic-intensity anticoagulation has also recently been conducted. This study was stopped early because therapeutic anticoagulation met the predeﬁned criteria for futility in the primary outcome
of organ support–free days.62 The preprint article for this study suggested that therapeutic anticoagulation did not improve hospital survival or days free of organ support, and a potential for harm could
not be excluded. When the results of this study are published, the
ASH guidelines will be updated accordingly.

 Studies examining the impact of anticoagulant therapy on thrombosis and bleeding outcomes in critically ill patients of differing
race and ethnicity
 Studies comparing mortality, thrombosis, bleeding, and functional outcomes with different available anticoagulant agents in
critically ill patients
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